Location of Repository

Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial

By Hiroyuki Konaka, Shin Egawa, Shiro Saito, Atsunori Yorozu, Hiroyuki Takahashi, Keiko Miyakoda, Masanori Fukushima, Takushi Dokiya, Hidetoshi Yamanaka, Nelson N Stone and Mikio Namiki
Topics: Study Protocol
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3350387
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Preview

    Citations

    1. (1995). A: A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer.
    2. (1997). A: Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. International journal of radiation oncology, biology, physics
    3. (2002). A: Treatment of prostate cancer with radiotherapy: should the entire seminal vesicles be included in the clinical target volume? International journal of radiation oncology, biology, physics
    4. (2006). al: Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer
    5. (1999). American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. International journal of radiation oncology, biology, physics
    6. (1997). Androgen deprivation and radiation therapy in prostate cancer: the evolving case for combination therapy. International journal of radiation oncology, biology, physics
    7. (2006). BS: Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. International journal of radiation oncology, biology, physics
    8. (2005). Cancer Trialists’ Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet
    9. (2007). Collette L: Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol
    10. (2009). Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials. Cancer
    11. (2005). Dritschilo A: Combined external beam radiotherapy and Pd-103 brachytherapy boost improves biochemical failure free survival in patients with clinically localized prostate cancer: results of a matched pair analysis. Prostate
    12. (2006). et al: Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA
    13. (1998). et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA
    14. (2009). et al: Duration of androgen suppression in the treatment of prostate cancer.
    15. (2009). et al: Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/ SFUO-3): an open randomised phase III trial. Lancet
    16. (2002). et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet
    17. (2009). et al: Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol
    18. (2008). et al: Ten-year followup of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.
    19. (1997). F: Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. International journal of radiation oncology, biology, physics
    20. (1998). FH: Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy.
    21. (1996). Flutamide-associated liver toxicity during treatment with total androgen suppression and radiation therapy for prostate cancer. Radiology
    22. (2007). G: 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. International journal of radiation oncology, biology, physics
    23. (2002). I: Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. International journal of radiation oncology, biology, physics
    24. (2003). Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy. Cancer
    25. (2010). Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes. International journal of radiation oncology, biology, physics
    26. (2007). Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features. Cancer
    27. (2000). Nadir BS: Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer
    28. (2006). NN: Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control. International journal of radiation oncology, biology, physics
    29. (2002). NN: Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. International journal of radiation oncology, biology, physics
    30. (1997). Pearson JD: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA
    31. (2003). PR: Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer.
    32. (2004). PR: The changing face of low-risk prostate cancer: trends in clinical presentation and primary management.
    33. (2004). Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose. International journal of radiation oncology, biology, physics
    34. (2001). SA: High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    35. (2008). Saigal CS, et al: Quality of life and satisfaction with outcome among prostate-cancer survivors.
    36. (1999). Stock RG: Prostate brachytherapy: treatment strategies.
    37. (2003). The effect of supplemental beam radiation on prostate brachytherapyrelated morbidity: morbidity outcomes from two prospective randomized multicenter trials. International journal of radiation oncology, biology, physics
    38. (2002). Theodorescu D: Multimodality radiotherapy and androgen ablation in the treatment of clinically localized prostate cancer: early results in high risk patients. Prostate Cancer Prostatic Dis
    39. (2004). Urinary and rectal complications of contemporary permanent transperineal brachytherapy for prostate carcinoma with or without external beam radiation therapy. Cancer
    40. (2005). Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using
    41. (2005). WU: Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA
    42. (2009). Y: AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: report of Task Group 137. Med Phys
    43. (2007). Yorozu A: Brachytherapy with permanent seed implantation.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.